News and features

Being overweight or obese is an important cause of rising cancer rates among younger adults in England, according to a major new study by researchers from The Institute of Cancer Research, London

Scientists have created the most comprehensive map to date of the genetic mutations that fuel cancer – opening the door to extending precision treatments to thousands more patients and offering clues as to why bowel cancer rates are rising in younger people.

Scientists at The Institute of Cancer Research, London, are supporting an international clinical trial of a promising new immunotherapy treatment for advanced ovarian cancer.

Two decades ago, a pivotal exchange between two scientists sparked a scientific and medical revolution. Professor Alan Ashworth, then Director of the Breast Cancer Now Toby Robins Research Centre at The Institute of Cancer Research, London, and his collaborator Professor Steve Jackson had long known that inherited genetic mutations in the genes BRCA1 and BRCA2 increase the risk of cancer. But, they wondered, what if those same mutations could be turned against the cancer itself?

The Institute of Cancer Research, London, has welcomed the approval of a new combination of two drugs for ovarian cancer by the US regulatory body the Food and Drug Administration (FDA).

Adaptive chemotherapy – a personalised approach to giving chemotherapy – can prolong survival in lab models of ovarian cancer, according to new results published in the journal Cancer Research.

Scientists at The Institute of Cancer Research, London, have identified a gene that affects how ovarian clear cell carcinoma (OCCC) could respond to a new class of drug called ATR inhibitors.

Ovarian cancer is often diagnosed late, making it difficult to treat. But innovative research at The Institute of Cancer Research, London, is changing how we think about managing this complex and hard-to-treat disease. Robbie Lockyer speaks to molecular pharmacology expert and medical oncologist Professor Udai Banerji to find out more about therapeutic research strategies.

Genetic testing to identify women with Lynch Syndrome is likely to need to increase dramatically to ensure that carriers are not missed, a new analysis by ICR researchers has found.

Researchers have carried out an in-depth analysis of 10,478 cancer genomes across 35 different cancer types, identifying 330 potential cancer-driving genes, 74 of which are newly associated with cancer. The findings highlight the potential to develop new, more targeted treatment options for cancer patients.

A combination of two drugs which can block the growth of cancer cells has shown promising results in women with a form of ovarian cancer that rarely responds to chemotherapy or hormone therapy.

Scientists have developed a new clinical pathway for testing for the cancer-causing faults in the BRCA gene that could ensure patients get the right treatment and boost the number of people who get tested.